Cassava Sciences announced Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer’s disease in the trial.

The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

While food and lifestyle changes can’t completely reverse the effects of Alzheimer’s disease, your plate could go a long way ...

"The NeuroAge Test represents a significant breakthrough in how we approach brain aging," said Dr. Christin Glorioso, CEO and Co-founder of NeuroAge Therapeutics. "Our test empowers individuals to ...

While food and lifestyle changes can't completely reverse the effects of Alzheimer's disease, your plate could go a long way ...

Many of us wonder how to slow down or completely stop the progression of Alzheimer's disease. It is considered a disease of civilization, turning those affected into individuals who may lose trust in ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

TAMPA — November marks National Alzheimer’s Disease Awareness Month. According to the Alzheimer’s Association, nearly 7 ...

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for ...

Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...

About 40% of dementia cases could be prevented or delayed by healthy lifestyle choices and preventive medicine. Here's a tool ...